Welcome to our dedicated page for Nuvectis Pharma SEC filings (Ticker: NVCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Nuvectis Pharma, Inc. filings document the regulatory disclosures of a Nasdaq-listed clinical-stage oncology drug developer with common stock registered under the Exchange Act. Recent Form 8-K reports furnish quarterly and annual financial results, corporate updates, and exhibit press releases describing development activity for NXP900 and related operating progress.
Proxy materials cover annual meeting matters, director elections, auditor ratification, board composition, and stockholder voting procedures. Other material-event filings record governance changes such as director appointments, while cover-page disclosures identify Nuvectis as an emerging growth company and list its common stock trading on the Nasdaq Capital Market under NVCT.
Hoberman Kenneth reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma, Inc. director Kenneth Hoberman received a grant of 35,000 shares of restricted common stock. The award was granted at no cash cost per share and is a form of equity compensation rather than an open-market purchase.
The 35,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, as long as Hoberman continues serving on the company’s Board of Directors. After this grant, he directly holds 168,140 shares of common stock, which includes restricted shares.
Oliviero James F III reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma director James F. Oliviero III received a grant of 35,000 shares of restricted common stock. These shares were awarded at no cash cost to him and are part of his equity compensation.
The restricted stock will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the company’s Board of Directors. Following this grant, he holds a total of 122,828 shares of Nuvectis Pharma common stock, including restricted shares.
Sanchez Juan reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma director Juan Sanchez received a grant of 35,000 shares of restricted common stock at no cost. The award will vest in equal annual installments over three years, starting on the first anniversary of the grant date, as long as he continues serving on the Board of Directors.
After this grant, Sanchez holds 113,380 common shares directly and 415 shares indirectly as custodian for his son. The filing also notes that his current holdings include 230 restricted shares that had been inadvertently omitted from his earlier Form 3.
Kaplan Matthew L. reported acquisition or exercise transactions in this Form 4 filing.
Nuvectis Pharma director Matthew L. Kaplan received a grant of 35,000 shares of restricted common stock. The award was made at no cash cost per share and is classified as a compensation-related grant rather than an open-market purchase.
The 35,000 restricted shares will vest in equal annual installments over three years, beginning on the first anniversary of the grant date, as long as Kaplan continues to serve on the Board of Directors on those dates. After this grant, he directly holds 159,760 shares of Nuvectis Pharma common stock, including restricted shares.
Nuvectis Pharma, Inc. reported the results of its 2026 Annual Meeting and corrected a share count error in its proxy. The Definitive Proxy Statement had stated 27,668,036 common shares outstanding as of April 13, 2026; the correct number was 26,614,628 shares.
The company stated this correction does not affect the validity or outcome of any votes. Stockholders representing 16,193,686 shares, or 60.8% of the 26,614,628 shares outstanding on the record date, were present, establishing a quorum. Stockholders elected Class I director Ron Bentsur and ratified Kesselman & Kesselman as independent registered public accounting firm for the year ending December 31, 2026.
Nuvectis Pharma reported first-quarter 2026 results, continuing as a clinical-stage oncology company with no product revenue. Net loss was $6.1 million, compared with $5.3 million a year earlier, driven by higher research and development and public-company costs.
Research and development expenses were $4.1 million and general and administrative expenses were $2.2 million. Cash and cash equivalents totaled $25.1 million at March 31 2026, which management believes can fund operations for at least 12 months.
The accumulated deficit reached $105.7 million. Shares outstanding rose to 26,525,533, reflecting equity-based compensation and modest use of the at-the-market program, which still has $60.0 million capacity within a broader $150.0 million shelf registration. Lead asset NXP900 remains in Phase 1b development.
Nuvectis Pharma reported first quarter 2026 results and highlighted progress in its NXP900 oncology program. Cash and cash equivalents were $25.1 million as of March 31, 2026, down from $31.6 million as of December 31, 2025, reflecting ongoing development spending.
The company recorded a net loss of $6.1 million for the quarter, compared with $5.3 million a year earlier, as research and development expenses rose to $4.1 million and general and administrative expenses to $2.2 million. Net loss per share was $0.26 based on 23.4 million weighted average shares outstanding.
Nuvectis is advancing NXP900, an oral small molecule SRC Family Kinase inhibitor, in an ongoing Phase 1b study, with a preliminary data readout expected in the summer of 2026. Preclinical data presented at AACR showed synergistic activity when NXP900 was combined with sotorasib in non-small cell lung cancer models.
Nuvectis Pharma, Inc. is holding a virtual Annual Meeting of Stockholders on June 11, 2026 at 10:00 a.m. Eastern Time via www.virtualshareholdermeeting.com/NVCT2026. Stockholders of record as of April 13, 2026, when 27,668,036 common shares were outstanding, are entitled to vote.
Stockholders will vote on electing co‑founder and CEO Ron Bentsur as a Class I director for a new three‑year term and on ratifying Kesselman & Kesselman, a member firm of PricewaterhouseCoopers International Limited, as independent registered public accounting firm for the year ending December 31, 2026.
The proxy details board structure, committee memberships, and independence determinations, and outlines executive and director pay, including significant restricted stock awards and change‑of‑control protections. Directors, executive officers, and 5% beneficial owners collectively control about 39.89% of the company’s common stock.
Nuvectis Pharma has filed a shelf registration statement on Form S-3 allowing it to offer up to $150,000,000 of common stock, preferred stock, warrants, debt securities and units over time. This structure lets the company raise capital in multiple transactions using a single overarching prospectus.
The filing includes a dedicated at-the-market program to sell up to $60,000,000 of common stock through Leerink Partners, with $45,580,233.34 of capacity carried over from a prior sales agreement prospectus. Nuvectis, an emerging growth oncology company, plans to use proceeds primarily to advance its NXP900 clinical program and other corporate needs, while retaining flexibility to issue different types of securities as market conditions and development plans evolve.